Literature DB >> 21989243

White matter disease: optimizing rituximab therapy for neuromyelitis optica.

Dean M Wingerchuk, Brian G Weinshenker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21989243     DOI： 10.1038/nrneurol.2011.154

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.

Authors:  J Shimizu; Y Hatanaka; M Hasegawa; A Iwata; I Sugimoto; H Date; J Goto; T Shimizu; M Takatsu; Y Sakurai; H Nakase; Y Uesaka; H Hashida; K Hashimoto; T Komiya; S Tsuji
Journal:  Neurology       Date:  2010-09-08       Impact factor: 9.910

2.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Authors:  H L Pellkofer; M Krumbholz; A Berthele; B Hemmer; L A Gerdes; J Havla; R Bittner; M Canis; E Meinl; R Hohlfeld; T Kuempfel
Journal:  Neurology       Date:  2011-04-12       Impact factor: 9.910

3.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.

Authors:  Su-Hyun Kim; Woojun Kim; Xue Feng Li; In-Ja Jung; Ho Jin Kim
Journal:  Arch Neurol       Date:  2011-07-11

4.  An open label study of the effects of rituximab in neuromyelitis optica.

Authors:  B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

6.  Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.

Authors:  Jacqueline Palace; Maria Isabel Leite; Angela Nairne; Angela Vincent
Journal:  Arch Neurol       Date:  2010-08

7.  Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.

Authors:  S R Hinson; S J Pittock; C F Lucchinetti; S F Roemer; J P Fryer; T J Kryzer; V A Lennon
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

8.  Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

Authors:  Shannon R Hinson; Andrew McKeon; James P Fryer; Metha Apiwattanakul; Vanda A Lennon; Sean J Pittock
Journal:  Arch Neurol       Date:  2009-09

Review 9.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

10.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08
  10 in total
  3 in total

1.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

Review 2.  Therapy of NMO spectrum disorders.

Authors:  Atanu Biswas; Arabinda Mukherjee
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

3.  Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

Authors:  Jui Dilip Jade; Srishti Bansi; Bhim Singhal
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.